Endocrinology — Clinical Immunology — Thyroid Oncology
Anti-thyroglobulin (anti-Tg antibodies)
Anti-thyroglobulin antibodies, known as anti-Tg or ATG, are autoantibodies directed against thyroglobulin, a large glycoprotein synthesized exclusively by thyroid follicular cells and serving as a protein matrix for the synthesis and storage of thyroid hormones T3 and T4. Their presence in serum reflects a breakdown in immune tolerance towards the thyroid gland, characteristic of autoimmune thyroid diseases, foremost among which is Hashimoto's thyroiditis and, to a lesser extent, Graves' disease. In current clinical practice, anti-Tg fulfils two distinct and complementary functions: on the one hand, it contributes to the diagnosis of autoimmune thyroiditis in association with anti-thyroperoxidase antibodies (anti-TPO), generally more sensitive and specific markers in this context; on the other hand, it is a major analytical interferent in the measurement of serum thyroglobulin, the reference biomarker for monitoring recurrence after treatment of differentiated thyroid cancer. It is in this second role that anti-Tg assays assume their greatest clinical importance, as their presence can distort thyroglobulin immunometry, leading to reassuring false-negative results that mask tumor recurrence. In Quebec, they are routinely prescribed as part of specialized thyroid assessments and post-thyroidectomy oncology follow-up.
Thyroglobulin: Target Antigen and Physiological Role
Understanding the physiological role of thyroglobulin is essential for grasping the clinical significance of antibodies directed against it and their implications in the two main contexts where they are measured.
| Aspect | Description |
|---|---|
| Structure | Very large homodimeric glycoprotein (660 kDa) synthesized and secreted by thyroid follicular cells (thyrocytes) into the follicular lumen; richly glycosylated (approximately 10 % of its mass) and iodinated in situ |
| Hormonal function | Serves as a precursor and reservoir for thyroid hormones: thyroxine (T4) and triiodothyronine (T3) are synthesized on the thyroglobulin molecule by iodination and coupling of tyrosine residues, then released by lysosomal hydrolysis upon stimulation by TSH. |
| Tissue specificity | Thyroid-exclusive synthesis; circulating thyroglobulin can only be produced by functional thyroid tissue, whether normal, benign (goiter), or malignant (differentiated thyroid carcinoma); this exclusivity makes thyroglobulin a reference tumor marker after total thyroidectomy. |
| Normal serum level | Variable depending on thyroid size and thyroid status: generally 1.5 to 38 ng/mL in euthyroidism in an adult with an intact thyroid; increases in cases of goiter, thyroiditis, TSH stimulation, or thyroid carcinoma; should be undetectable or very low after total thyroidectomy with successful radioiodine ablation |
| Self-immunization mechanism | During thyroid inflammation or cell lysis, excess thyroglobulin released can exceed the immune tolerance capacity in genetically predisposed individuals (HLA-DR3, HLA-DR5 alleles, CTLA-4, PTPN22 polymorphisms); presentation of thyroglobulin peptides to self-reactive T lymphocytes triggers the autoimmune cascade. |
Reference values and measurement technique
The dosage of anti-Tg is performed on serum using an immunoenzymatic or immunofluorimetric technique. Threshold values vary depending on the analytical platforms, but the principle of interpretation remains uniform.
| Parameter | Details |
|---|---|
| Units | International Units per milliliter (IU/mL) or Arbitrary Units per milliliter (U/mL) depending on the analytical platform |
| Usual positivity threshold | Greater than 115 IU/mL on Roche Elecsys platforms (most common reference value in Quebec); the specific threshold of the performing laboratory must always be consulted |
| Prevalence in the general population | Anti-Tg positive in 3 to 18 % of the general adult population, according to studies; more frequent in women (female to male ratio of 3 to 5 to 1) and with advancing age |
| Withholding | Serum (serum-separator tube or dry tube); no specific fasting requirements; stable for several days at 4°C and several months at -20°C; ideally to be measured on the same analytical platform during oncological follow-up to ensure comparability of results |
| Cross-platform variability | Anti-Tg values are not interchangeable between different analytical platforms (Roche, Abbott, Siemens, Beckman); a change of platform during monitoring requires reconstituting the patient's individual reference value on the new system. |
| Relation with anti-TPO | Anti-TPO (anti-thyroid peroxidase antibodies) and anti-Tg are often co-present in Hashimoto's thyroiditis; anti-TPO are more sensitive for the diagnosis of Hashimoto's (positive in 95 % of cases vs 60 to 80 % for anti-Tg); anti-Tg can be positive alone in 5 to 10 % of Hashimoto's cases |
International standardization of anti-Tg assays remains imperfect: values obtained on different analytical platforms are not directly comparable and can vary by a factor of three for the same sample. In the context of post-thyroidectomy oncological monitoring, it is imperative that all sequential anti-Tg and thyroglobulin assays be performed on the same analytical platform, ideally in the same laboratory, to allow for reliable trend interpretation.
Role in autoimmune thyroid diseases
Anti-thyroglobulin antibodies (anti-Tg) fall within the spectrum of thyroid autoantibodies, the presence of which reflects autoimmune activation against the thyroid gland. They are not directly pathogenic in themselves, unlike the anti-TSH receptor antibodies (TRAK) in Graves' disease, but their high titer indicates the intensity of the underlying autoimmune inflammatory process.
| Thyroid disease | Anti-TG positivity rate | Clinical role of anti-Tg |
|---|---|---|
| Hashimoto's thyroiditis (chronic lymphocytic thyroiditis) | 60 to 80 % of cases | A diagnostic marker complementary to anti-TPO; their titer can fluctuate with the progression of the disease; a very high titer is associated with more active thyroid inflammation and an increased risk of progressive hypothyroidism. |
| Graves' disease (autoimmune hyperthyroidism) | 30 to 60 % of cases | Associated marker, generally at a lower level than in Hashimoto's; TRAKs (TSH receptor antibodies) remain the specific marker for Graves' disease; elevated anti-Tg may indicate a mixed Graves'-Hashimoto's component. |
| Postpartum thyroiditis | 70 to 90 % of cases | Positivity of anti-Tg (and anti-TPO) during pregnancy or postpartum predicts the risk of postpartum thyroiditis and subsequent permanent hypothyroidism. |
| Silent (painless) thyroiditis | 50 to 70 % of cases | Autoimmune form of transient destructive thyroiditis; anti-Tg contribute to the differential diagnosis with factitious thyrotoxicosis and subacute De Quervain's thyroiditis (which is of viral origin and generally seronegative). |
| Type 1 diabetes and other autoimmune diseases | 20 to 30 % of patients | Frequent association in the context of autoimmune polyendocrine syndromes (APS type 2 or Schmidt's syndrome); screening for anti-Tg and anti-TPO is recommended in type 1 diabetics |
| General population with no known thyroid disease | 3 to 18 % depending on the studies | Isolated weakly positive anti-Tg antibodies, often without immediate clinical significance; warrant monitoring of thyroid function (annual TSH) and clinical follow-up |
Hashimoto's Thyroiditis: Clinical Presentation
Hashimoto's thyroiditis is the most common cause of acquired hypothyroidism in developed countries, affecting approximately 5 % of adult women in Canada, with a peak incidence between 30 and 50 years of age and a female-to-male ratio of 7 to 10 to 1. It results from progressive lymphocytic infiltration and autoimmune destruction of the thyroid parenchyma, leading to a gradual reduction in the gland's secretory capacity.
- Initial phase (Hashimoto's thyrotoxicosis or hashitoxicosis): acute follicular lysis massively releasing stored T3 and T4, causing transient thyrotoxicosis of a few weeks; often unrecognized as it spontaneously resolves; may mimic early Graves' disease
- Euthyroid phase: normal thyroid function despite high autoantibodies; can last years to decades; normal TSH but already elevated anti-TPO and anti-Tg
- Subclinical hypothyroidism phase: isolated elevation of TSH (generally between 4 and 10 mIU/L) with normal free T4; absent or mild symptoms (mild fatigue, moderate cold intolerance); warrants close monitoring and discussion about the appropriateness of replacement therapy.
- Overt hypothyroidism phase: elevated TSH and low free T4; complete clinical picture with profound fatigue, cold intolerance, weight gain, constipation, bradycardia, psychomotor slowing, depression, dry skin, hair loss, menstrual irregularities; substitutive treatment with levothyroxine indicated
- Hashimoto's goiter: The thyroid gland can be enlarged (goiter) during active phases of inflammation, then progressively shrink over the years with the gradual destruction of parenchyma (terminal thyroid atrophy in advanced forms).
- Rare complications: primary thyroid lymphoma (60 to 80 times higher risk than the general population, mainly MALT type); Hashimoto's encephalopathy (rare neuro-psychiatric manifestation, steroid-responsive)
Role of Anti-Tg in Differentiated Thyroid Cancer Monitoring
It is within the oncological context that anti-Tg antibodies hold their most critical clinical importance. After total thyroidectomy for papillary or follicular thyroid carcinoma, with or without radioiodine remnant ablation (radioiodine, I-131), serum thyroglobulin is the reference tumor marker for detecting locoregional recurrences and distant metastases. The presence of anti-Tg antibodies in serum profoundly disrupts this surveillance.
| Problem | Mechanism and consequences |
|---|---|
| Analytical interference with thyroglobulin immunoassays (IMA) | Anti-Tg antibodies bind to circulating thyroglobulin and form immune complexes that interfere with antibody capture in the assay kit, resulting in a falsely low or undetectable thyroglobulin result, even in the presence of a secreting tumor recurrence. This poses a risk of falsely negative reassurance, which could delay the detection of a recurrence. |
| Alternative assay technique: recovery method or mass spectrometry assay (LC-MS/MS) | LC-MS/MS mass spectrometry allows for the quantification of thyroglobulin without interference from antibodies; it directly measures thyroglobulin peptides after enzymatic digestion, independently of the presence of anti-Tg; available in some specialized laboratories; recommended when anti-Tg are positive and thyroglobulin measurement by immunoassay is deemed unreliable. |
| Using anti-Tg as a surrogate marker for monitoring | In the absence of normal residual thyroid tissue (after total thyroidectomy and successful radioiodine ablation), anti-Tg should progressively decline and then become undetectable within a few years if no recurrence is present; persistence, a rise, or a lack of decline in anti-Tg should raise suspicion of recurrence or residual tumor; the longitudinal monitoring of anti-Tg titer thus constitutes an indirect marker of tumor recurrence in this context. |
| Half-life of anti-Tg after total thyroidectomy | After complete ablation of all thyroid tissue (tumor and normal), the biological half-life of anti-Tg is approximately 3 months for immunoglobulin G; a gradual normalization is expected in 2 to 4 years in the absence of recurrence; persistence beyond 5 years or a secondary rise after initial decline are warning signs justifying imaging re-evaluation. |
The fundamental rule of thyroid cancer follow-up is simple and should never be forgotten: any thyroglobulin measurement must be accompanied by a simultaneous anti-Tg measurement. An undetectable or low thyroglobulin result associated with positive anti-Tg antibodies cannot be interpreted as reassuring. Analytical interference renders the immunometric thyroglobulin result unreliable and potentially falsely negative in this context. It is then the evolving trend of the anti-Tg antibodies themselves that becomes the primary follow-up marker.
Kinetics of anti-Tg after differentiated thyroid cancer treatment
Longitudinal monitoring of anti-Tg antibodies after total thyroidectomy follows precise interpretation rules, based on the expected dynamics according to whether the tumor removal was complete or not.
| Evolution of anti-Tg after treatment | Clinical interpretation | Recommended driving |
|---|---|---|
| Gradual and steady decline to undetectable in 2 to 4 years | Sign of complete biological remission; corresponds to the progressive elimination of the antigenic stimulus (disappearance of normal and tumor thyroid tissue) | Continuation of annual serological monitoring according to the defined surveillance protocol based on the initial cancer risk level |
| Plateau or slow decline without normalization after 3 to 5 years | Can indicate residual thyroid tissue (normal or tumorous) that persists, or a significant autoimmune thyroid condition maintaining antigenic stimulus. | Imaging re-evaluation (cervical ultrasound, whole-body radioiodine scan if indicated, FDG-PET scan if recurrence is suspected); specialized endocrinology consultation |
| Secondary resurgence after a period of decline | Strong alarm signal for local, nodal, or distant recurrence; correlation with proven tumor recurrence in numerous cohort studies | Full staging workup: cervical ultrasound with fine-needle aspiration if a suspicious lymph node is found, whole-body scintigraphy, fluorodeoxyglucose (FDG)-PET scan using either sodium fluoride or fluorocholine depending on availability; thyroid oncology consultation. |
| High retention rate with no significant decline in the first year | Suggests incomplete ablation or significant residual disease; may also reflect a major coexisting autoimmune diathesis unrelated to tumor recurrence | Thyroglobulin assay by LC-MS/MS if available; cervical ultrasound; re-evaluation of radioiodine ablation completeness; multidisciplinary team meeting discussion |
Complete thyroid panel associated
Anti-thyroglobulin antibodies are never prescribed or interpreted in isolation. They are part of a structured thyroid assessment, the composition of which varies depending on the clinical context, whether it is for the diagnosis of autoimmune disease or for post-surgical oncological follow-up.
- TSH (Thyroid-Stimulating Hormone): the primary marker of thyroid function; its elevation indicates early or overt hypothyroidism; its decrease suggests hyperthyroidism or therapeutic suppression in the context of oncological follow-up; first-line test for any thyroid assessment
- Free T4 (free thyroxine): complements TSH for assessing the severity of hypothyroidism or hyperthyroidism and measuring the adequacy of levothyroxine replacement therapy; essential for detecting TSH/free T4 discrepancies
- Anti-thyroperoxidase (anti-TPO): the most sensitive autoimmune marker for Hashimoto's thyroiditis (positive in 95% of cases); always prescribed in conjunction with anti-Tg in the workup for autoimmune thyroiditis; more specific than anti-Tg for the diagnosis of Hashimoto's
- Serum thyroglobulin (in an oncological context): reference tumor marker after total thyroidectomy; must be accompanied by simultaneous anti-Tg dosage for reliable interpretation; ideally measured under stimulation by exogenous TSH (recombinant human TSH) or after levothyroxine withdrawal to maximize sensitivity
- Thyrotropin receptor antibodies (TRAb): specific marker for Graves' disease; measured in cases of suspected autoimmune hyperthyroidism, pregnancy in a woman with Graves' disease, or etiological workup for exophthalmos
- Thyroid cervical ultrasound: essential in the initial assessment of any thyroid disease; evaluates the morphology, volume, and echostructure of the thyroid (hypoechoic heterogeneous appearance characteristic of Hashimoto's), nodules, and cervical lymphadenopathy; reference examination for post-thyroidectomy oncological follow-up.
- Calcitonin (in case of a suspicious thyroid nodule): marker for parafollicular C-cells, useful for screening medullary thyroid carcinoma; not to be confused with thyroglobulin, which is exclusively related to differentiated carcinomas of follicular origin.
Non-thyroid causes of elevated anti-Tg
Although anti-thyroglobulin positivity is highly suggestive of autoimmune thyroid pathology, a few non-thyroid conditions can be accompanied by a low-amplitude elevation, generally at levels below those observed in Hashimoto's thyroiditis.
| Context | Positivity rate | Remarks |
|---|---|---|
| Other autoimmune diseases (lupus, rheumatoid arthritis, Sjögren's syndrome) | 5 to 15 % of patients | Anti-Tg usually low titre; to be interpreted in clinical context; screening for associated hypothyroidism recommended in connective tissue diseases |
| Differentiated thyroid carcinoma (pre-treatment) | 20 to 30 % of patients | Anti-Tg can be positive preoperatively in thyroid cancer, regardless of associated thyroiditis; their preoperative presence indicates analytical interference that will complicate post-therapeutic monitoring. |
| Normal pregnancy | Slight physiological increase possible | Pregnancy can transiently alter anti-Tg levels; screening for autoimmune thyroiditis during pregnancy is recommended in women at risk (personal or family history, suggestive symptoms). |
| General elderly population | Up to 18 % after 60 years | Increased prevalence of antithyroid antibodies with age, particularly in women; may reflect undiagnosed subclinical thyroiditis or an age-related immune phenomenon |
| Iodine deficiency or iodine overload | Variable | Variations in iodine intake can modulate the expression of thyroid autoantibodies; an iodine overload (iodinated medications, contrast agents) can trigger autoimmune thyroiditis in predisposed individuals. |
Tracking and support according to context
The action to take in the presence of positive anti-Tg antibodies depends entirely on the clinical context in which they are discovered. The two most frequent situations are the initial diagnostic workup for thyroid disease and oncological follow-up after thyroidectomy.
| Context | Recommended driving |
|---|---|
| Anti-Tg positive with overt hypothyroidism (high TSH, low free T4) | Probable diagnosis of Hashimoto's thyroiditis; initiation of levothyroxine sodium (Synthroid, Eltroxin) replacement therapy with gradual adjustment according to target TSH; quarterly biological monitoring until stable, then biannual or annual; thyroid ultrasound monitoring according to evolution. |
| Positive for anti-thyroglobulin antibodies with subclinical hypothyroidism (elevated TSH, normal free T4) | Individual discussion on the indication for replacement therapy according to TSH level, symptoms, contemplated or ongoing pregnancy, and cardiovascular comorbidities; if therapeutic abstention, TSH and anti-TPO monitoring every 6 to 12 months |
| Isolated Anti-Tg positive with euthyroid (normal TSH) | No treatment; patient information on the risk of progression to hypothyroidism (approximately 2 to 4 % per year); annual TSH monitoring; initial thyroid ultrasound |
| Positive Anti-Tg tests during follow-up after thyroidectomy for differentiated cancer | Simultaneous measurement of thyroglobulin by LC-MS/MS if available; quarterly or semi-annual monitoring of anti-Tg titers as an indirect marker of recurrence; reassessment by imaging if anti-Tg does not decline or if it increases; multidisciplinary consultation in thyroid oncology |
| Positive Anti-Tg found during pregnancy | Close monitoring of TSH (first trimester, then every trimester); screening for postpartum thyroiditis after delivery; levothyroxine substitution if TSH is greater than 2.5 mIU/L in the first trimester in the presence of positive anti-TPO or anti-Tg according to Canadian guidelines |
Consult at Clinique Omicron
Clinique Omicron welcomes patients at its Quebec branches for complete thyroid assessments, including anti-thyroglobulin antibodies, anti-TPO, TSH, and other markers as indicated by the clinical picture. Our physicians ensure the interpretation of results, initial management of autoimmune thyroid diseases, monitoring of substituted hypothyroidism, and referrals to endocrinologists and thyroid oncology teams when necessary. Book an appointment at your nearest branch.
The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.